Dr. Weihong Zhao 赵卫红
Chief Physician, Associate Professor
Department of Medical Oncology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and comprehensive treatment of malignant tumors, including breast, lung, gastrointestinal, urinary system cancers, and soft tissue sarcomas, using chemotherapy, targeted therapy, endocrine therapy, and bioimmunotherapy.
Dr. Zhao holds a doctorate in oncology from Peking Union Medical College and has over 20 years of experience in medical oncology. Dr. Zhao conducts research on drug resistance and participates in national research projects and international multi-center clinical trials. Dr. Zhao has published over 20 papers and co-authored books on breast cancer and tumor metastasis.
Professional roles
- Executive Committee Member, China Geriatric Oncology Society
- Review Expert, Beijing Natural Science Foundation
Name order: in Chinese the family name comes first (Zhao Weihong). Papers usually list the name as Weihong Zhao or Zhao W.
Selected publications
21 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Breast Cancer (Dove Med Press), 2025 (senior author): Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter and Retrospective Study. PubMed 39877556
- Immun Inflamm Dis, 2024 (senior author): Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity. PubMed 38270321
- Oncologist, 2022 (senior author): Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer. PubMed 35380719
- Invest New Drugs, 2021 (senior author): Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer. PubMed 33140143
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion